{
    "root": "303c849b-1f11-4ca6-e063-6294a90a96e9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Myrbetriq",
    "value": "20250313",
    "ingredients": [
        {
            "name": "POLYETHYLENE OXIDE 2000000",
            "code": "5K3991GVWI"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "MIRABEGRON",
            "code": "MVR3JL3B2V"
        }
    ],
    "indications": "myrbetriq beta-3 adrenergic agonist indicated treatment : overactive bladder ( oab ) adult patients symptoms urge urinary incontinence , urgency , urinary frequency , either alone combination muscarinic antagonist solifenacin succinate . ( 1.1 ) neurogenic detrusor overactivity ( ndo ) pediatric patients aged 3 years older weighing 35 kg . ( 1.2 ) myrbetriq granules beta-3 adrenergic agonist indicated treatment ndo pediatric patients aged 3 years older . ( 1.2 )",
    "contraindications": "myrbetriq myrbetriq granules two different products substitutable milligram-per-milligram basis . select recommended product ( myrbetriq myrbetriq granules ) based indication patient ’ weight . combine myrbetriq myrbetriq granules achieve total dose . recommended myrbetriq granules adults determined . ( 2.1 ) oab adults recommended starting dose myrbetriq 25 mg orally daily , either alone combination solifenacin succinate 5 mg orally daily . ( 2.2 ) 4 8 weeks , myrbetriq dose may increased 50 mg orally daily . ( 2.2 ) ndo pediatric patients 3 years older pediatric patients weighing less 35 kg : myrbetriq granules : recommended starting dose myrbetriq granules weight-based administered extended-release oral suspension daily . 4 8 weeks , increase lowest effective dose without exceeding maximum recommended dose . ( 2.3 ) pediatric patients weighing 35 kg : myrbetriq myrbetriq granules : recommended starting myrbetriq 25 mg orally daily . 4 8 weeks , myrbetriq dose may increased 50 mg orally daily . ( 2.3 ) recommended starting myrbetriq granules , administered extended-release oral suspension , 6 ml ( 48 mg ) orally daily . 4 8 weeks , increase maximum myrbetriq granules 10 ml ( 80 mg ) orally daily ( 2.3 ) adult pediatric patients renal hepatic impairment : refer full prescribing information recommended . ( 2.4 , 2.5 ) preparation myrbetriq granules : refer full prescribing information . ( 2.6 ) myrbetriq : adult patients : swallow myrbetriq whole water . chew , divide , crush . take without food . ( 2.7 ) pediatric patients : swallow myrbetriq whole water . chew , divide , crush . take food . ( 2.7 ) myrbetriq granules : pediatric patients : take myrbetriq granules prepared extended-release oral suspension . take food . ( 2.7 )",
    "warningsAndPrecautions": "myrbetriq supplied oval , film-coated , extended-release tablets , available shape/color : oval/yellow , branding tablet : logo 355 , ndc : 70518-2435-00 ndc : 70518-2435-01 ndc : 70518-2435-02 ndc : 70518-2435-03 ndc : 70518-2435-04 packaging : 90 1 bottle plastic packaging : 30 1 box packaging : 1 1 pouch packaging : 30 1 box packaging : 1 1 pouch store 20°c 25°c ( 68°f 77°f ) excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "myrbetriq/myrbetriq granules contraindicated patients known hypersensitivity mirabegron inactive ingredients tablet oral suspension [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 )",
    "contraindications_original": "MYRBETRIQ and MYRBETRIQ Granules are two different products and they are not substitutable on a milligram-per-milligram basis. Select the recommended product (MYRBETRIQ or MYRBETRIQ Granules) based on the indication and patient’s weight. Do not combine MYRBETRIQ and MYRBETRIQ Granules to achieve the total dose. A recommended dosage for MYRBETRIQ Granules for adults has not been determined. ( 2.1 ) OAB in Adults The recommended starting dose of MYRBETRIQ is 25 mg orally once daily, either alone or in combination with solifenacin succinate 5 mg orally once daily. ( 2.2 ) After 4 to 8 weeks, the MYRBETRIQ dose may be increased to 50 mg orally once daily. ( 2.2 ) NDO in Pediatric Patients 3 Years and Older Pediatric Patients weighing less than 35 kg: Use MYRBETRIQ Granules: The recommended starting dose of MYRBETRIQ Granules is weight-based and administered as an extended-release oral suspension once daily. After 4 to 8 weeks, increase to the lowest effective dose without exceeding the maximum recommended dose. ( 2.3 ) Pediatric Patients weighing 35 kg or more: Use MYRBETRIQ or MYRBETRIQ Granules: The recommended starting dosage of MYRBETRIQ is 25 mg orally once daily. After 4 to 8 weeks, the MYRBETRIQ dose may be increased to 50 mg orally once daily. ( 2.3 ) The recommended starting dosage of MYRBETRIQ Granules, administered as an extended-release oral suspension, is 6 mL (48 mg) orally once daily. After 4 to 8 weeks, increase to a maximum dosage of MYRBETRIQ Granules 10 mL (80 mg) orally once daily ( 2.3 ) Adult or Pediatric Patients with Renal or Hepatic Impairment : Refer to the full prescribing information for recommended dosage. ( 2.4 , 2.5 ) Preparation for MYRBETRIQ Granules : Refer to the full prescribing information. ( 2.6 ) Administration MYRBETRIQ: Adult patients: Swallow MYRBETRIQ whole with water. Do not chew, divide, or crush. Take with or without food. ( 2.7 ) Pediatric patients: Swallow MYRBETRIQ whole with water. Do not chew, divide, or crush. Take with food. ( 2.7 ) MYRBETRIQ Granules: Pediatric patients: Take MYRBETRIQ Granules prepared as an extended-release oral suspension. Take with food. ( 2.7 )",
    "warningsAndPrecautions_original": "MYRBETRIQ is supplied as oval, film-coated, extended-release tablets, available in\n                  Shape/color: oval/yellow, Branding on Tablet: logo 355,\n                  NDC: 70518-2435-00\n                  NDC: 70518-2435-01\n                  NDC: 70518-2435-02\n                  NDC: 70518-2435-03\n                  NDC: 70518-2435-04\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20°C to 25°C (68°F to 77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "MYRBETRIQ/MYRBETRIQ Granules is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet or oral suspension\n \n  [see Adverse Reactions (\n  \n   6.1,\n  \n   6.2)]\n \n  ."
}